Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

Smoking kills one in two regular smokers, but quitting at any point in life leads to big improvements in health, increased life expectancy and savings in healthcare costs. That’s why we need a range of ways to help people quit – and new evidence shows that paying people to quit is one way to boost quit rates.

Our recently updated Cochrane review looked at the evidence from 33 trials and found strong evidence that incentive programmes help people to quit smoking, increasing quit rates at six months or longer by about 50%. In these programmes, smokers who could prove they’d quit smoking were rewarded financially. Some have expressed concern that smokers would return to smoking once the financial rewards ended, but the studies showed that people stayed smoke free, even after the rewards finished.

Read the full article on The Conversation website, written by Jamie Hartmann-Boyce (Nuffield Department of Primary Care Health Sciences) and Caitlin Notley (University of East Anglia)

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.